Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Kyowa Hakko Kirin begins phase III trial of hepatocellular carcinoma drug

Kyowa Hakko Kirin begins phase III trial of hepatocellular carcinoma drug

14th February 2014

Kyowa Hakko Kirin has begun a phase III trial of a new cancer drug originally developed by ArQule.

The Japanese clinical study will evaluate ARQ 197 (tivantinib) among patients with c-Met diagnostic-high inoperable hepatocellular carcinoma treated with one prior sorafenib therapy. A total of 160 people will be enrolled for the trial.

This randomised, double-blind placebo-controlled study aims to compare progression-free survival of ARQ197 versus placebo. The oral agent was licensed by Kyowa Hakko Kirin from ArQule through an Asia-specific agreement signed in April 2007.

It is expected that the trial will run from January 2014 to December 2016.

A statement from the company said: "Kyowa Hakko Kirin has four strategic categories including the oncology area, and is endeavoring to contribute to the treatment of cancer patients through the further development of anticancer agents."

Last month, the firm announced its financial results for 2013, during which it achieved a year-on-year improvement in sales, thanks in part to the rising profitability of its UK subsidiary ProStrakan.ADNFCR-8000103-ID-801693646-ADNFCR

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.